Optimising the management of choroidal neovascularisation in Asian patients: consensus on treatment recommendations for anti-VEGF therapy

Singapore Medical Journal

Volumn 52, Issue 4, 2011, Pages 232-240

  Koh, A ^a   Lim, T H ^c   Au Eong, K G ^e   Chee, C ^e   Ong, S G ^b   Tan, N ^d   Yeo, I ^a   Wong, D ^a  

^a Eye and Retina Surgeons   (Singapore)

^b NATIONAL HEALTHCARE GROUP EYE INSTITUTE   (Singapore)

^c MOUNT ELIZABETH MEDICAL CENTRE   (Singapore)

^d NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^e SINGAPORE NATIONAL EYE CENTRE   (Singapore)

Author keywords

Age related macular degeneration; Choroidal neovascularisation; Monoclonal antibody; Ranibizumab

Indexed keywords

BEVACIZUMAB; CORTICOSTEROID; PLACEBO; RANIBIZUMAB; TRIAMCINOLONE ACETATE; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VERTEPORFIN;

ARTICLE; ASIAN; CHOROID DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; ENDOPHTHALMITIS; EVIDENCE BASED MEDICINE; EYE INFLAMMATION; HUMAN; MONOTHERAPY; MYOPIA; PATHOGENESIS; PHOTODYNAMIC THERAPY; POLYPOIDAL CHOROIDAL VASCULOPATHY; PRACTICE GUIDELINE; PUNCTATE INNER CHOROIDOPATHY; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION;

ALGORITHMS; ANTIBODIES, MONOCLONAL; ASIA; CHOROIDAL NEOVASCULARIZATION; CLINICAL TRIALS AS TOPIC; GUIDELINES AS TOPIC; HUMANS; MULTICENTER STUDIES AS TOPIC; MYOPIA; PHOTOCHEMOTHERAPY; RETINA; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79958262185     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Campochiaro PA, Soloway P, Ryan SJ, Miller JW. The pathogenesis of choroidal neovascularization in patients with age-related macular degeneration. Mol Vis 1999; 5:34.
2. Au Eong KG. Age-related macular degeneration: An emerging challenge for eye care and public health professionals in the Asia Pacific region. Ann Acad Med Singapore 2006; 35:133-5.
3. Chopdar A, Chakravarthy U, Verma D. Age-related macular degeneration. BMJ 2003; 326:485-8.
4. Chan WM, Ohji M, Lai TY, et al. Choroidal neovascularisation in pathological myopia: an update in management. Br J Ophthalmol 2005; 89:1522-8.
5. Woo JH, Sanjay S, Au Eong KG. The epidemiology of age-related macular degeneration in the Indian subcontinent. Acta Ophthalmol 2009; 87:262-9.
6. AMD Alliance International. Awareness of age related macular degeneration and associated risk factors. AMD Global Report 2005. Toronto: AMD Alliance International, 2005.
7. Sanjay S, Neo HY, Sangtam T, et al. Survey on the knowledge of age-related macular degeneration and its risk factors among Singapore residents. Clin Experiment Ophthalmol 2009; 37:795-800.
8. Pe'er J, Shweiki D, Itin A, et al. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 1995; 72:638-45.
9. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005; 46:726-33.
10. Iu LP, Kwok AK. An update of treatment options for neovascular age-related macular degeneration. Hong Kong Med J 2007; 13:460-70.
11. Brown DA, Regillo CD. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: Applying clinical trial result to the treatment of everyday patients. Am J Opthalmol 2007; 144:627-37.
12. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular agerelated macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009; 148: 43-58.e1.
13. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351:2805-16.
14. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1419-31.
15. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1432-44.
16. Boyer D, Antoszyk A, Awh CC, et al. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007; 114:246-52.
17. Krebs I, Lie S, Stolba U, et al. Efficacy of intravitreal bevacizumab (Avastin) therapy for early and advanced neovascular age-related macular degeneration. Acta Ophthalmol 2008; 87:611-7.
18. Pedersen KB, Sjølie AK, Møller F. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients. Acta Ophthalmol 2009; 87: 714-9.
19. Weinberger AWA, Thiel M, Mohammadi B, et al. Retinal pigment epithelium tears after intravitreal bevacizumab in pigment epithelium detachment. Am J Ophthalmol 2007; 144:294-6.
20. Chang LK, Sarraf D. Tears of the retinal pigment epithelium: an old problem in a new era. Retina 2007; 27:523-34.
21. Chan CK, Meyer CH, Gross JG, et al. Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular agerelated macular degeneration. Retina 2007; 27:541-51.
22. Ronan SM, Yoganathan P, Chien FY, et al. Retinal pigment epithelium tears after intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Retina 2007; 27:535-40.
23. Chan CK, Lin SG. Retinal pigment epithelial tear after ranibizumab therapy for subfoveal fibrovascular pigment epithelial detachment. Eur J Ophthalmol 2007; 17:674-6.
24. Garg S, Brod R, Kim D, et al. Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration. Clin Experiment Ophthalmol 2008; 36:252-6.
25. Smith BT, Kraus CL, Apte RS. Retinal pigment epithelial tears in ranibizumab-treated eyes. Retina 2009; 29:335-9.
26. Chan CK, Abraham P, Meyer CH, et al. Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections. Retina 2010; 30:203-11.
27. Schmidt-Erfurth U, Schlötzer-Schrehard U, Cursiefen C, et al. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003; 44:4473-80.
28. Heier JS, Boyer DS, Ciulla TA, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS study. Arch Ophthalmol 2006; 124:1532-42.
29. Ley AM, et al. Combination therapy with verteporfin PDT and ranibizumab: Twelve-month efficacy and safety results of the MONT BLANC study. Presented at AAO 2009; Abstract PA005.
30. Gomi F, Sawa M, Sakaguchi H, et al. Efficacy of Intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol 2008; 92:70-3.
31. Spaide RF, Donsoff I, Lam DL, et al. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy. Retina 2002; 22:529-35.
32. Chan WM, Lam DS, Lai TY, et al. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series. Ophthalmology 2004; 111:1576-84.
33. Chan WM, Liu DT, Lai TY, et al. Extensive submacular haemorrhage in polypoidal choroidal vasculopathy managed by sequential gas displacement and photodynamic therapy: a pilot study of one-year follow up. Clin Experiment Ophthalmol 2005; 33:611-8.
34. Silva RM, Figueira J, Cachulo ML, et al. Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol 2005; 243:973-9.
35. Mauget-Faÿsse M, Quaranta-El Maftouhi M, De La Marnièrre E, Leys A. Photodynamic therapy with verteporfin in the treatment of exudative idiopathic polypoidal choroidal vasculopathy. Eur J Ophthalmol 2006; 16:695-704.
36. Akaza E, Yuzawa M, Matsumoto Y, et al. Role of photodynamic therapy in polypoidal choroidal vasculopathy. Jpn J Ophthalmol 2007; 51:270-7.
37. Eandi CM, Ober MD, Freund KB, Slakter JS, Yannuzzi LA. Selective photodynamic therapy for neovascular agerelated macular degeneration with polypoidal choroidal neovascularization. Retina 2007; 27:825-31.
38. Hirami Y, Tsujikawa A, Otani A, et al. Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy. Retina 2007; 27:335-41.
39. Otani A, Sasahara M, Yodoi Y, et al. Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 2007; 144:7-14.
40. Gomi F, Ohji M, Sayanagi K, et al. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology 2008; 115:141-6.
41. Tong JP, Chan WM, Liu DT, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Opthalmol 2006; 141:456-62.
42. Lai TY, Chan WM, Liu DT, Luk FO, Lam DS. Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Br J Ophthalmol 2008; 92:661-6.
43. Blinder KJ, Blumenkranz MS, Bressler NM, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial - VIP report no. 3. Ophthalmology 2003; 110:667-73.
44. Hussain N, Das T, Vashist U, Sumashri K. Verteporfin therapy for myopic choroidal neovascularisation in Indian eyes (one year results). Indian J Ophthalmol 2004; 52:227-31.
45. Krebs I, Binder S, Stolba U, et al. Choroidal neovascularization in pathologic myopia: three-year results after photodynamic therapy. Am J Ophthalmol 2005; 140:416-25.
46. Pece A, Vadalà M, Isola V, Matranga D. Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization in pathologic myopia: a long-term follow-up study. Am J Ophthalmol 2007; 143:449-54.
47. Hayashi K, Ohno-Matsui K, Teramukai S, et al. Photodynamic therapy with verteporfin for choroidal neovascularization of pathologic myopia in Japanese patients: comparison with nontreated controls. Am J Ophthalmol 2008; 145:518-26.
48. Ruiz-Moreno JM, Amat P, Montero JA, Lugo F. Photodynamic therapy to treat choroidal neovascularisation in highly myopic patients: 4 years' outcome. Br J Ophthalmol 2008; 92:792-4.
49. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization six-month results of a prospective pilot study. Ophthalmology 2007; 114:2190-6.
50. Wu PC, Chen YJ. Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up. Eye (Lond) 2009; 23:2042-5.
51. Yoon JU, Byun YJ, Koh HJ. Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization. Retina 2010; 30:418-24.
52. Cohen SY, Bulik A, Dubois L, Quentel G. Photodynamic therapy for juxtafoveal choroidal neovascularization in myopic eyes. Am J Ophthalmol 2003; 136:371-4.